Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 21%
Hold 50%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is set to have a strong first quarter as their Growth Products show positive trends, and the management team has confidence in the growth of their drug Eliquis. With a focus on attracting investors, the company plans to continue their research and development efforts in their core therapeutic areas, while also seeking out new potential treatments such as their CELMoDs. Additionally, recent positive updates, such as BMY's guidance ahead of consensus and positive results from Bayer's asundexian trial, have increased the company's transformative potential and make it a strong buy for investors.

Bears say

Bristol-Myers Squibb is facing potential downside risks due to the possibility of more successful Phase 3 results from competitors in rare cardiovascular, inflammatory and oncology areas, as well as the risk of their own pipeline programs failing in clinical trials. Additionally, potential delays in regulatory approvals and any adverse macroeconomic or policy-related developments could also negatively impact the company's financial performance. As a result, the financial analyst has a negative outlook on the stock, despite the company's strong position in the immuno-oncology space.

Bristol-Myers (BMY) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 14 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.